Testing for coronavirus
icon-infectious-disease-testing
Syndromic testing

The future of infectious disease diagnostics

Patients with infectious illnesses often have signs and symptoms that are indicative of a disease, but that aren't specific enough to clinically distinguish what makes them ill. These patients are frequently given broad treatment, heavy monitoring and possibly unnecessary interventions. This puts a burden on healthcare systems, clinical labs and clinicians, and means patients aren't getting the best care possible.

We’re committed to helping healthcare workers like you navigate the challenges of diagnosing infectious diseases. That’s why we’ve developed an easy-to-use, automated diagnostic testing system that can help eliminate the guesswork and make your job easier. Our tests use multiplex PCR technology – also known as syndromic testing – that can quickly survey many different pathogens in a single patient sample. With syndromic testing, you get the answers you need, when you need them. And your patients get better care, faster.
icon-infectious-disease-testing
Enhance your monkeypox research with the QIAstat-Dx Viral Vesicular Panel
Your lab in the palm of your hand 

What if you could monitor your diagnostic testing status anytime, anywhere? And get around-the-clock proactive technical support? It’s possible with QIAstat-Dx connectivity, powered by QIAsphere.*

New to rapid diagnostics with syndromic testing?
Find the information you need and learn how to incorporate syndromic testing into your diagnostic strategy.
Get fast answers for central nervous system infections

Rapid diagnosis of central nervous system infections is crucial for successful patient outcomes. That's why we've introduced a new syndromic panel that can differentiate 15 pathogens in around 1 hour.

Dr. Celestin Alexis Agbessi
“It changed our perception, our prescription habits, and it will change the way we work in the future. In the end, we gain money for both the community and the patients. That is really a big step forward.”

Celestin Alexis Agbessi, M.D., Bichat-Claude Bernard Hospital, Paris

Michelle Volk
“It’s hugely beneficial to be able to test for that wide range of pathogens. Ruling out COVID is helpful, but so is the chance to correctly identify other illnesses so physicians can treat the patients and their symptoms appropriately.”

Michelle Volk, CEO and president of Great Lakes Labs, Indiana, USA

Joshua Arant
“Our value to our patients and to our provider community has increased by bringing the QIAstat-Dx in-house.”

Joshua Arant, Founder and Chief Operations Officer, Mako Medical

icon-cta-contact
Have a question about multiplex panel testing?
Get in touch with us today.
References
  1. Yalamanchili H, et al. (2018) Gastroenterol Hepatol, 14(11):646-652
  2. Binnicker M. Multiplex. (2015) J. Clin Microbiology, 53(12):3723-3728
  3. Macfarlane-Smith L, et al. (2018) Gastrointestinal Infections, 34(1):19-2
  4. Echavarria M, et al. (2018) J Clin Virol, 108:90–95
  5. Beal S G, et al. (2018) J Clin Microbiol, 18;56(1)
  6. Bouzid D, et al. (2020) J Hospital Infection, 337-338
  7. Iroh Tam PY, et al. (2017) Children (Basel), 4(1)
  8. Zhu et al. (2018) Clin Pediatr, 58(2): 185-190
  9. Martinez RM, et al. (2016) Clinical Virology Symposium, Poster #C-368

*Some features require a QIAstat-Dx Connectivity plan. Flexible plans are available to meet your lab’s needs.

The QIAstat-Dx Viral Vesicular Panel is for research use only. The QIAstat-Dx Viral Vesicular Panel is run on the QIAstat-Dx Analyzer.

The QIAstat-Dx Analyzer, QIAstat-Dx Rise, QIAstat-Dx Respiratory SARS-CoV-2 Panel and QIAstat-Dx Gastrointestinal Panel are intended for in vitro diagnostic use. 

The QIAstat-Dx ME Panel is indicated as an aid in the diagnosis of specific agents that cause meningitis and/or encephalitis, and results must be used in conjunction with other clinical, epidemiological, and laboratory data. Results from the QIAstat-Dx ME Panel are not intended to be used as the sole basis for diagnosis, treatment, or other patient management decisions. Positive results do not rule out co-infection with organisms not included in the QIAstat-Dx ME Panel. The agent or agents detected may not be the definite cause of the disease. Negative results do not preclude central nervous system (CNS) infection. 

The QIAstat-Dx ME Panel is intended for in vitro diagnostic use by laboratory professionals only.

Product availability may differ from country to country based on regulations and approvals. Contact your country representative for further details. 

For up-to-date licensing information and product-specific disclaimers, see the respective QIAGEN kit instructions for use or user manual. QIAGEN instructions for use and user manuals are available at www.qiagen.com or can be requested from QIAGEN Technical Services (or your local distributor).